Bone formation and resorption in tissue culture. Effect of agents implicated in renal osteodystrophy

1970 ◽  
Vol 126 (5) ◽  
pp. 887-890 ◽  
Author(s):  
L. G. Raisz
2010 ◽  
Vol 54 (2) ◽  
pp. 87-98 ◽  
Author(s):  
Carolina A. Moreira Kulak ◽  
David W. Dempster

Bone histomorphometry is a quantitative histological examination of an undecalcified bone biopsy performed to obtain quantitative information on bone remodeling and structure. Labeling agents taken before the procedure deposit at sites of bone formation allowing a dynamic analysis. Biopsy is indicated to make the diagnosis of subclinical osteomalacia, to characterize the different forms of renal osteodystrophy and to elucidate cases of unexplained skeletal fragility. Bone histomorphometric parameters are divided into structural and remodeling subgroups, with the latter being subdivided into static and dynamic categories. Metabolic bone disorders such as osteomalacia, hyperparathyroidism, hypothyroidism, osteoporosis and renal osteodystrophy display different histomorphometric profiles. Antiresorptive and anabolic drugs used for the treatment of osteoporosis also induce characteristic changes in the bone biopsy. Bone histomorphometry is an important research tool in the field of bone metabolism and provides information that is not available by any other investigative approach.


2013 ◽  
Vol 9 (8) ◽  
pp. 7908-7916 ◽  
Author(s):  
Mark S.F. Clarke ◽  
Alamelu Sundaresan ◽  
Charles R. Vanderburg ◽  
Meredith G. Banigan ◽  
Neal R. Pellis

1987 ◽  
Vol 36 (22) ◽  
pp. 4007-4012 ◽  
Author(s):  
Masayoshi Yamaguchi ◽  
Hidetoshi Oishi ◽  
Yasunobu Suketa

Radiology ◽  
1974 ◽  
Vol 110 (3) ◽  
pp. 513-522 ◽  
Author(s):  
H. Erik Meema ◽  
Dimitrios G. Oreopoulos ◽  
Sol Rabinovich ◽  
Harry Husdan ◽  
Abraham Rapoport

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Syazrah Salam ◽  
Orla Gallagher ◽  
Fatma Gossiel ◽  
Arif Khwaja ◽  
Richard Eastell

Abstract Background and Aims Renal osteodystrophy is common in advanced chronic kidney disease (CKD) patients and is characterized by abnormal bone turnover and mineralization. Parathyroid hormone (PTH) increases bone turnover through osteoblast and osteoclast activation. Osteoprotegerin (OPG) is a decoy receptor of receptor activator of nuclear factor kappa-β ligand and thus, inhibits osteoclast maturation. Meanwhile, sclerostin is an inhibitor of the Wnt signalling pathway and thus, inhibits osteoblast maturation. We aimed to assess the relationship between these bone regulatory markers and bone turnover as assessed by bone histomorphometry and bone turnover markers (BTMs). Method We recruited 43 CKD patients with eGFR<30ml/min/1.73m2 or on dialysis. Fasting serum samples were analysed using Immunodiagnostic Systems automated assays (Boldon, UK) for intact PTH (iPTH) and BTMs such as bone alkaline phosphatase (bALP) and intact procollagen type 1 N-terminal propeptide (intact PINP) which are bone formation markers, and tartrate-resistant acid phosphatase 5b (TRAP5b) which is a bone resorption marker. OPG and sclerostin were analysed using manual ELISA by Biomedica (Vienna, Austria). Trans-iliac bone biopsy was performed after tetracycline labelling. Bone samples were analysed using quantitative histomorphometry. Normal bone turnover was defined as bone formation rate/bone surface (BFR/BS) of 18 - 38µm3/µm2/year. Spearman rank correlation was used to test the relationship between the variables. Results Median BFR/BS was 32.12 (IQR 17.76 – 48.25) um3/um2/year. 26% of patients had low and 40% had high bone turnover. iPTH and OPG were positively correlated with BFR/BS (rho = 0.42, p<0.01 and rho = 0.36, p<0.05 respectively). Sclerostin was not correlated with BFR/BS. Furthermore, sclerostin did not correlate with bALP and intact PINP whereas OPG correlated with TRAP5b (rho = 0.43, p<0.01). iPTH correlated with bALP (rho = 0.62, p<0.001), intact PINP (rho = 0.62, p<0.001) and TRAP5b (rho = 0.50, p = 0.001). Conclusion Circulating levels of iPTH and OPG were modestly associated with bone turnover but sclerostin was not. There are likely to be bone regulators other than iPTH, OPG and sclerostin which regulate bone turnover in renal osteodystrophy.


1989 ◽  
Vol 69 (6) ◽  
pp. 1166-1173 ◽  
Author(s):  
PIERRE J. MARIE ◽  
ABDERRAHIM LOMRI ◽  
MARIE CHRISTINE DE VERNEJOUL ◽  
CAROLINE MORIEUX ◽  
ANNE-MARIE GRAULET ◽  
...  

1989 ◽  
Vol 12 (11) ◽  
pp. 708-715 ◽  
Author(s):  
Masayoshi YAMAGUCHI ◽  
Mayumi UTO ◽  
Ryukichi MATSUI

Sign in / Sign up

Export Citation Format

Share Document